Noopur Raje, MD
Enriched profileProfessor of Medicine, Harvard Medical School; Director, Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center; Rita M. Kelley Chair in Oncology · Massachusetts General Hospital Cancer Center
Noopur Raje is Professor of Medicine, Harvard Medical School; Director, Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center; Rita M. Kelley Chair in Oncology at Massachusetts General Hospital Cancer Center. OpenAlex indexes 1,044 publications with 45,084 citations (h-index 104); ClinicalTrials.gov lists 9 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 15 Oct 2026
Noopur Raje, MD, is Professor of Medicine, Harvard Medical School at Massachusetts General Hospital Cancer Center / Harvard Medical School, Boston, MA. The public record shows 1,044 publications with 45,084 citations (h-index 104), centered on Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, CAR-T cell therapy research. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 24 companies.
- Most recent indexed publication: 2026 · Blood cancer journal
- Top research focus: Multiple Myeloma Research and Treatments
- 9 registered trials on ClinicalTrials.gov
- Open Payments reporting from 24 companies
Generated from the cited public record · current as of 15 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 18 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 378.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Public positions
sourced statements on record- Member
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines Committee for Multiple Myeloma
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancernetwork.com ↗ - Co-Chair
National Cancer Institute (NCI) Myeloma Steering Committee
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancernetwork.com ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 15 Oct 2026
Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:
- A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Sponsor: Kelonia Therapeutics, Inc.
- ELISA in Relapsed/Refractory MM
Sponsor: Massachusetts General Hospital
- Elranatamab in R/R Multiple Myeloma
Sponsor: Massachusetts General Hospital
Industry payments
Updated 15 Oct 2026
24 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20257 payments$17,993openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year20255 payments
- Janssen Global Services, LLCProgram year20255 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
33.1%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor33.1%Acyclovir100%Part D≥21 patientsAnti-infectives
23.5%Macrolide Antimicrobial23.5%Azithromycin100%Part D≥22 patientsSensory organs
20.6%Corticosteroid11.8%Dexamethasone100%Part D≥13 patientsFluoroquinolone Antibacterial8.8%Ciprofloxacin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 15 Oct 2026
157 congress contributions (2009–2025) across AACR, ASCO, ASH, ASTRO, ESMO per OpenAlex. The most recent:
- Implementing the bispecific outpatient safe step-up (BOSS) program for elranatamab in ambulatory treatment of multiple myeloma.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 15 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study.
Cancer immunology research
Clinical Trial2026 - Body Composition Metrics Associated with Time to Progression in Smoldering Multiple Myeloma.
Diagnostics (Basel, Switzerland)
Article2025 - Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma.
Journal of clinical oncology
Article2025 - International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.
Journal of clinical oncology
Guideline2025
Most-cited works
by citation count (OpenAlex)- 01Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma2,445 citations2021
- 02Multiple myeloma2,176 citations2000
- 03
- 04Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations1,736 citations2015
- 05
Network
Updated 15 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 15 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/noopur-raje-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/noopur-raje-8405724
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Noopur-Raje
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/NoopurRajeMD
Mentions by others
where others cite or feature them- Other
massgeneral.org/charged/episodes/noopur-raje
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →massgeneral.org ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 15 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.massgeneralbrigham.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.massgeneralbrigham.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.massgeneralbrigham.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.massgeneralbrigham.org ↗
Editorial & leadership roles
journal and society appointments- Secretary
International Myeloma Society
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myelomasociety.org ↗ - Member
International Myeloma Working Group (IMWG)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myelomasociety.org ↗ - Ad hoc peer reviewer for Blood
Clinical Cancer Research, Leukemia, and American Journal of Hematology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancernetwork.com ↗
Awards & honors
honors on the public record- Brian G.M. Durie Outstanding Achievement Award (Kyle and Durie Achievement Award)
International Myeloma Foundation (IMF) / International Myeloma Working Group (IMWG)
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →biospace.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →myelomasociety.org ↗
Secondary affiliations
appointments beyond the home institution- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncologynewscentral.com ↗
Media & interviews
press, podcasts and appearances- "Noopur Raje, MD: Breaking the Mold to Improve Multiple Myeloma Treatment"
Charged podcast (Mass General), Episode #24, April 2019
2019provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →massgeneral.org ↗ - Video interview contributor
VJHemOnc (hematology/oncology video media platform)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Andrew Yee, MD
Massachusetts General Hospital Cancer Center
Jacob Soumerai, MD
Massachusetts General Hospital Cancer Center
Kenneth Anderson, MD
Dana-Farber Cancer Institute
Paul Richardson, MD
Dana-Farber Cancer Institute
S Rajkumar, MD
Mayo Clinic
Meletios Dimopoulos, MD
National and Kapodistrian University of Athens